###begin article-title 0
###xml 58 59 58 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
Characterization of NF-kB-mediated inhibition of catechol-O-methyltransferase
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 9 10 9 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
###xml 257 263 <span type="species:ncbi:9606">humans</span>
Catechol-O-methyltransferase (COMT), an enzyme that metabolizes catecholamines, has recently been implicated in the modulation of pain. Specifically, low COMT activity is associated with heightened pain perception and development of musculoskeletal pain in humans as well as increased experimental pain sensitivity in rodents.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 160 165 152 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 174 184 166 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(P2-COMT) </italic>
###xml 388 396 368 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
###xml 440 448 416 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
We report that the proinflammatory cytokine tumor necrosis factor alpha (TNFalpha) downregulates COMT mRNA and protein in astrocytes. Examination of the distal COMT promoter (P2-COMT) reveals a putative binding site for nuclear factor kappaB (NF-kappaB), the pivotal regulator of inflammation and the target of TNFalpha. Cell culture assays and functional deletion analyses of the cloned P2-COMT promoter demonstrate that TNFalpha inhibits P2-COMT activity in astrocytes by inducing NF-kappaB complex recruitment to the specific kappaB binding site.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
Collectively, our findings provide the first evidence for NF-kappaB-mediated inhibition of COMT expression in the central nervous system, suggesting that COMT contributes to the pathogenesis of inflammatory pain states.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 9 10 9 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
###xml 163 164 163 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 165 166 165 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 332 333 332 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 334 335 334 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 416 417 416 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 418 419 418 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 496 497 496 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 604 605 601 602 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 615 616 609 610 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 639 640 633 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 437 445 <span type="species:ncbi:9606">patients</span>
Catechol-O-methyltransferase (COMT) metabolizes catecholamines and thereby acts as a key modulator of dopaminergic and adrenergic/noradrenergic neurotransmission [1,2]. Converging lines of evidence have revealed an important role of COMT in the etiology and pathogenesis of a wide variety of central nervous system (CNS) disorders [2-4]. Recently, COMT has also been implicated in the regulation of pain perception [5,6]. Myofacial pain patients exhibit lower COMT activity relative to controls [7], and COMT inhibition increases pain sensitivity in rodents by promoting catecholamine stimulation of beta2- and beta3-adrenergic receptors [8].
###end p 9
###begin p 10
###xml 251 254 251 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P1 </italic>
###xml 265 268 265 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2 </italic>
###xml 293 294 293 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 351 353 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 491 495 491 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">via </italic>
###xml 523 525 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 679 681 679 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 829 831 829 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 898 900 898 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 946 948 946 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 949 951 949 951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 194 199 <span type="species:ncbi:9606">human</span>
###xml 219 223 <span type="species:ncbi:10116">rats</span>
The COMT protein exists in two major forms: a shorter soluble form (S-COMT) and a longer membrane-bound form (MB-COMT). They are encoded from one gene by two mRNA transcripts (1.3 and 1.5 kb in human, 1.6 and 1.9 kb in rats) regulated by the proximal P1 and distal P2 promoters, respectively [9-11]. Only the longer transcript was found in the brain [12] with the predominant protein being MB-COMT. However, S-COMT protein is also expressed in the brain from the longer MB-COMT mRNA isoform via a leaky scanning mechanism [13]. Though their sequences are largely homologous, MB-COMT has approximately a 10-fold greater affinity for dopamine and noradrenaline relative to S-COMT [14]. Seven novel COMT mRNA variants have also been detected in brain, however, they likely to exist at much lower levels than the primary transcript [15]. Although recent reports describe a neuronal expression of COMT [16], it is primarily considered a glial enzyme [17-19].
###end p 10
###begin p 11
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 324 326 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 327 329 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 531 533 527 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 633 635 625 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 636 638 628 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 738 740 722 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 741 743 725 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 870 872 850 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 873 875 853 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 876 878 856 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1127 1129 1095 1097 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1442 1444 1383 1385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1562 1564 1492 1494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 80 88 <span type="species:ncbi:9606">patients</span>
A significant role for glia in mediating pain has been implicated by studies of patients with persistent pain conditions and animal models of pain [20-22]. Proinflammatory cytokines are produced and released by activated microglia and astrocytes in the CNS as well as by immune cells at the site of injury or inflammation. [23-26]. TNFalpha is widely considered to be the prototypic proinflammatory cytokine due to its principal role in initiating the cascade of cytokines and growth factors involved in the inflammatory response [20]. Tissue levels of TNFalpha have been correlated with pain report in a number of painful diseases [27-29]. TNFalpha activates NF-kappaB, which is the pivotal regulator of cellular inflammatory responses [30-32]. Specifically, the NF-kappaB pathway plays one of the major roles in injury or inflammation-evoked activation of astrocytes [23,33,34]. Within the nervous system, NF-kappaB is most frequently composed of two DNA-binding subunits (p65/Rel A and p50) that form a complex with the inhibitory subunit IkappaB which normally retains NF-kappaB within the cytoplasm of unstimulated cells [35]. Signal-induced phosphorylation, ubiquitination, and degradation of IkappaB triggers NF-kappaB nuclear translocation and DNA binding. Phosphorylation of IkappaB is mediated by the IkappaB kinase (IKK) complex, which consists of two catalytic subunits, IKKalpha and IKKbeta, and the regulatory subunit IKKgamma [36]. Gene knock-out studies have established an essential role for IKKbeta in TNFalpha-induced activation of NF-kappaB [37].
###end p 11
###begin p 12
###xml 166 168 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 169 171 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 306 308 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 414 416 402 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 417 419 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 558 560 542 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 561 563 545 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
A growing number of reports reveal a crucial role of NF-kappaB in nociception. NF-kappaB activity is increased in animal models of neuropathic and inflammatory pain [38-42]. A specific IKK inhibitor reverses heightened pain sensitivity to noxious (hyperalgesia) and normally innocuous stimuli (allodynia) [43]. Increased neuropathic and inflammatory pain is suppressed by pretreatment with an NF-kappaB inhibitor [39,44]. Interestingly, selective inactivation of NF-kappaB in glial cells or astrocytes leads to decreased pain and better functional recovery [45-47].
###end p 12
###begin p 13
###xml 186 188 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 189 191 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 192 194 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 195 197 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 198 200 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
Despite increasing evidence for an important role of NF-kappaB in pain regulation, very few studies have addressed the mechanisms whereby this pathway exerts its effects on nociception [38,39,41,43,48]. We hypothesized that NF-kappaB regulates expression of COMT, an enzyme known to contribute to enhanced pain states. Thus, the present study explored the relationship between the NF-kappaB pathway and COMT expression in order to gain an understanding of the cellular mechanisms underlying inflammatory pain.
###end p 13
###begin title 14
Results
###end title 14
###begin title 15
TNFalpha inhibits endogenous COMT expression in astrocytes
###end title 15
###begin p 16
###xml 272 274 264 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 335 337 327 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 352 354 344 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 509 511 497 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 526 528 514 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 853 855 825 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 84 87 <span type="species:ncbi:10116">rat</span>
To elucidate a potential role of TNFalpha in regulating COMT expression, we treated rat primary astrocytes with TNFalpha and measured COMT protein levels using Western blot analysis. A significant reduction in COMT protein expression was observed beginning at 8 h (Figure 1A) with a 60% maximal decrease relative to untreated control (P < 0.05; Figure 1B). Using quantitative real-time RT-PCR analysis, we further demonstrated a down-regulation of MB-COMT mRNA at 0.5 h and 30 h following TNFalpha treatment (P < 0.01; Figure 1C). This oscillatory rather than linear pattern of MB-COMT mRNA expression is in agreement with previously reported characteristics of NF-kB-mediated gene regulation and has been associated with autoregulation of NF-kappaB activity, as one of the genes activated by NF-kappaB is that encoding its own inhibitor, IkappaBalpha [49]. Finally, a dye exclusion test verified that the TNFalpha-dependent down-regulation of COMT was not due to cytotoxic effects as more than 95% of cells treated with TNFalpha remained viable (data not shown).
###end p 16
###begin p 17
###xml 0 66 0 62 <bold xmlns:xlink="http://www.w3.org/1999/xlink">COMT expression is downregulated by TNF&#945; in primary astrocytes</bold>
###xml 430 432 416 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 445 447 431 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
COMT expression is downregulated by TNFalpha in primary astrocytes. Administration of TNFalpha (20 ng/ml) decreases COMT protein expression in primary astrocytes as indicated by (A) a representative Western blot and (B) quantitative analysis of Western blots from experiments performed in triplicate. (C) Administration of TNFalpha (20 ng/ml) also decreases MB-COMT mRNA expression in primary astrocytes. Data are Means +/- SEM. *P < 0.05 and **P < 0.01 different from untreated control.
###end p 17
###begin title 18
###xml 52 57 52 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 39 44 <span type="species:ncbi:9606">human</span>
Cloning and structural analysis of the human distal COMT promoter
###end title 18
###begin p 19
###xml 105 110 101 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 119 129 115 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(P2-COMT) </italic>
###xml 182 184 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 251 259 247 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
###xml 287 289 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 290 292 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 370 372 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 92 97 <span type="species:ncbi:9606">human</span>
To study the signaling mechanisms whereby TNFalpha regulates COMT expression, we cloned the human distal COMT promoter (P2-COMT) which controls transcription of MB-COMT mRNA (Figure 2A). A 1.5 kb DNA fragment corresponding to the previously published P2-COMT sequences [GenBank:  and ] [11,50] was cloned in the pGL3 luciferase reporter vector. Using TFSearch database [51], we analyzed the cloned sequence and identified a number of potential transcription factor binding elements that can affect both constitutive and tissue-specific expression of COMT gene, such as TATA and CAAT boxes, CRE, C/EBP, and NF-kappaB sites. The presence of the NF-kappaB consensus binding site 5'-GGGGACGCCC-3' at position -109 from the first transcription initiation site of MB-COMT indicated that this promoter could be regulated by NF-kappaB pathway and respond to TNFalpha treatment.
###end p 19
###begin p 20
###xml 12 20 12 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
###xml 0 80 0 76 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Activity of <italic>P2-COMT </italic>promoter is downregulated by TNF&#945; in H4 astroglial cells</bold>
###xml 113 118 109 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 466 478 458 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT/Luc </italic>
###xml 555 557 537 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 568 570 550 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 699 707 669 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
###xml 733 747 703 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3x-&#954;B/Luc </italic>
###xml 874 876 832 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 107 112 <span type="species:ncbi:9606">human</span>
Activity of P2-COMT promoter is downregulated by TNFalpha in H4 astroglial cells. (A) Schematic diagram of human COMT gene. The exon-intron organization is not to scale. The positions of translation start codons for MB-COMT (MB-ATG) and S-COMT (S-ATG) polypeptides, translation stop codon (TGA), putative polyadenylation signal (AATTAA), promoter regions, and primers (U1 and D1) are shown. (B) Administration of TNFalpha (20 ng/ml) inhibits activity of transfected P2-COMT/Luc reporter in H4 but not in H4 IkappaBalpha-SR cells. Data are Means +/- SEM. *P < 0.05, ***P < 0.001 H4 different from H4 IkappaBalpha-SR cells at 16 and 24 h, respectively. (C) TNFalpha-mediated inhibition is specific to P2-COMT promoter. The activity of 3x-kappaB/Luc reporter (kappaB consensus sites from the MHC class I promoter) was tested after treatment with TNFalpha (20 ng/ml) for 24 h. *P < 0.05 different from untreated control.
###end p 20
###begin title 21
COMT inhibition by TNFalpha requires NF-kappaB activation
###end title 21
###begin p 22
###xml 90 98 86 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
###xml 125 137 121 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT/Luc </italic>
###xml 313 321 305 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
###xml 398 406 386 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
###xml 465 467 453 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 478 480 466 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 527 529 515 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 579 587 563 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
###xml 820 832 788 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT/Luc </italic>
###xml 846 854 814 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
###xml 996 1004 948 956 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
###xml 1021 1023 973 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 119 124 <span type="species:ncbi:9606">human</span>
###xml 180 185 <span type="species:ncbi:9606">human</span>
Luciferase reporter gene assays were employed to test the effect of TNFalpha treatment on P2-COMT activity. A chimeric human P2-COMT/Luc construct was transiently transfected into human H4 astroglioma cells. Consistent with the observed down-regulation of endogenous COMT expression, TNFalpha treatment decreased P2-COMT activity in time-dependent manner. After a 24-hour incubation with TNFalpha, P2-COMT activity was reduced to 60% relative to untreated control (P < 0.05 and P < 0.001 at 16 h and 24 h, respectively; Figure 2B). To test if the TNFalpha-mediated inhibition of P2-COMT activity requires NF-kappaB pathway activation, H4 astroglial cells stably transfected with IkappaBalpha super-repressor (SR), a nondegradable dominant-negative inhibitor of all NF-kappaB complexes, were transiently transfected with P2-COMT/Luc construct and P2-COMT activity was measured during 24 h of TNFalpha treatment. H4 IkappaBalpha-SR cells were no longer sensitive to TNFalpha-mediated inhibition of P2-COMT activity (Figure 2B).
###end p 22
###begin p 23
###xml 514 522 494 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
###xml 541 543 521 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 558 560 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
As NF-kappaB is generally recognized as a positive regulator of gene expression, we used a reporter vector with a promoter known to be up-regulated in response to NF-kappaB activation. A luciferase reporter vector containing kappaB consensus sites from the MHC class I promoter was transfected into H4 astroglioma cells. After treatment with TNFalpha, the MHC promoter reporter showed a 14-fold increase in expression, demonstrating that the TNFalpha-mediated inhibition of COMT expression in astroglioma cells is P2-COMT promoter specific (P < 0.05; Figure 2C).
###end p 23
###begin p 24
###xml 286 288 258 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 317 319 289 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 343 348 315 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A, B</xref>
###xml 354 356 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
Finally, to test effect of NF-kappaB pathway on endogenous COMT expression, we also treated H4 IkappaBalpha-SR cells with TNFalpha. Consistent with reporter assay results, TNFalpha was unable to significantly repress endogenous COMT protein and mRNA levels in H4 IkappaBalpha-SR cells (P > 0.05 for protein level and P > 0.05 for mRNA; Figure 3A, B, and 3C).
###end p 24
###begin p 25
###xml 0 89 0 77 <bold xmlns:xlink="http://www.w3.org/1999/xlink">TNF&#945;-mediated repression of COMT is attenuated in H4 I&#954;B&#945;-SR astroglial cells</bold>
###xml 390 392 366 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
TNFalpha-mediated repression of COMT is attenuated in H4 IkappaBalpha-SR astroglial cells. Administration of TNFalpha (100 ng/ml) does not reduce COMT expression in H4 IkappaBalpha-SR cells as indicated by (A) a representative Western blot, (B) quantitative analysis of Western blots from experiments performed in triplicate, and (C) quantitative real-time RT-PCR analysis of MB-COMT mRNA. P > 0.05 different from untreated control.
###end p 25
###begin title 26
###xml 23 27 19 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">via </italic>
TNFalpha inhibits COMT via a canonical NF-kappaB activation mechanism
###end title 26
###begin p 27
###xml 25 29 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">via </italic>
###xml 91 93 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 190 195 178 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 342 350 323 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
###xml 439 447 417 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
###xml 457 459 435 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 474 476 452 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
As TNFalpha may function via NF-kappaB and JUN N-terminal kinase (JNK) signaling cascades [52], we sought to determine whether a signal that elicits NF-kappaB activation alone would repress COMT gene expression. Thus, we tested if overexpression of p65 or IKKbeta, which are both essential for NF-kappaB activation, would negatively regulate P2-COMT activity. Our data demonstrate that p65 or IKKbeta overexpression dramatically decreases P2-COMT activity (P < 0.01; Figure 4A).
###end p 27
###begin p 28
###xml 0 45 0 41 <bold xmlns:xlink="http://www.w3.org/1999/xlink">NF-&#954;B is required for COMT downregulation</bold>
###xml 119 131 112 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT/Luc </italic>
###xml 188 190 179 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 212 224 203 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT/Luc </italic>
NF-kappaB is required for COMT downregulation. (A) Cotransfection of pCMV-SPORT-M-p65 or pCMV-SPORT-M-IKKbeta inhibits P2-COMT/Luc reporter activity in H4 cells. Data are Means +/- SEM. **P < 0.01 different from P2-COMT/Luc alone. Western blot analysis was performed with protein extracts from H4 cells treated with TNFalpha (20 ng/ml) for the indicated timepoints. Expression of IkappaBalpha was evaluated in cytoplasmic fraction of H4 cells (B), whereas p65 and p50 protein levels were tested in nuclear extracts (C).
###end p 28
###begin p 29
###xml 458 460 430 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 465 467 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4C</xref>
###xml 517 519 485 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
Next, we examined whether TNFalpha engaged the canonical mechanism of IkappaBalpha phosphorylation and degradation to trigger transport of NF-kappaB to the nucleus in our experimental conditions. H4 cells were treated with TNFalpha and then cytoplasmic and nuclear extracts analyzed by Western blot. The degradation of IkappaBalpha in the cytoplasmic fraction of the cells and simultaneous increase in the nuclear level of p65 was observed at 30 min (Figure 4B and 4C), characteristic of dynamic NF-kappaB signaling [53]. Together, these results demonstrate that TNFalpha initiates the canonical IkappaBalpha degradation pathway to activate NF-kappaB in H4 astroglioma cells, and that NF-kappaB activation inhibits COMT in glial cells.
###end p 29
###begin title 30
###xml 63 71 59 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
Identification of the functional NF-kappaB binding site in the P2-COMT promoter
###end title 30
###begin p 31
###xml 51 59 47 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
###xml 123 135 119 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT/Luc </italic>
###xml 212 214 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 418 426 406 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
###xml 436 442 424 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Del.2 </italic>
###xml 600 602 572 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 617 619 589 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
###xml 624 626 596 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5C</xref>
###xml 731 737 691 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Del.1 </italic>
###xml 807 815 763 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
###xml 835 837 791 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 861 863 817 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 907 909 855 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
###xml 914 916 862 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5C</xref>
###xml 1026 1034 970 978 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
To identify the NF-kappaB-responsive region in the P2-COMT promoter, we analyzed the activity of serial 5'deletions of the P2-COMT/Luc constructs transiently transfected into H4 or H4 IkappaBalpha-SR cells (Fig. 5A). Consequent deletions of 5'fragments led to a graduate increase in overall basal promoter activity in all constructs, suggesting the presence of serial putative negatively regulating elements along the P2-COMT promoter. Del.2 construct that lack the putative kappaB consensus binding site also showed a lack of response to TNFalpha treatment in either H4 or H4 IkappaBalpha-SR cells (P > 0.05; Figure 5B and 5C). Conversely, TNFalpha treatment of H4 but not H4 IkappaBalpha-SR cells inhibited activity of construct Del.1 containing the putative kappaB consensus binding site and the initial P2-COMT promoter construct (P < 0.05 for H4 cells and P > 0.05 for H4 IkappaBalpha-SR cells; Figure 5B and 5C). Thus, the region between position -155 and -33 appears to be crucial for TNFalpha-dependent suppression of P2-COMT activity.
###end p 31
###begin p 32
###xml 52 60 48 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
###xml 0 68 0 64 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Identification of TNF&#945;-responsive region in the <italic>P2-COMT </italic>promoter</bold>
###xml 99 111 95 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT/Luc </italic>
###xml 146 152 142 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Del.1 </italic>
###xml 156 161 152 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Del.2</italic>
###xml 247 266 239 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT/Luc, Del.1 </italic>
###xml 270 276 262 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Del.2 </italic>
###xml 370 372 352 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 748 756 714 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
###xml 897 905 855 863 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
###xml 969 972 925 928 <sup xmlns:xlink="http://www.w3.org/1999/xlink">###</sup>
###xml 972 974 928 930 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1036 1038 988 990 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1112 1114 1056 1058 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Identification of TNFalpha-responsive region in the P2-COMT promoter. (A) Schematic diagram of the P2-COMT/Luc construct and its serial deletions Del.1 and Del.2. The effect of TNFalpha (20 ng/ml, 8 h of treatment) on the relative activity of the P2-COMT/Luc, Del.1 and Del.2 constructs transfected into H4 (B) and H4 IkappaBalpha-SR (C) cells. Data are Means +/- SEM. *P < 0.05 different from untreated control. (D) Binding of p65 to a plate-immobilized oligonucleotide containing a kappaB binding site was measured by TransAM NF-kappaB assay in the nuclear extracts from H4 cells 30 min post TNFalpha treatment. This activation was prevented by competition with a wild-type binding control (WT BC) kappaB consensus oligonucleotide or a wild-type P2-COMT kappaB consensus oligonucleotide (WT P2). Oligonucleotides with mutated kappaB binding sites - a mutant binding control (MT BC) and a mutant P2-COMT (MT P2-COMT) - had little or no effect. Data are Means +/- SEM. ###P < 0.001 TNFalpha-treated different from untreated control, ***P < 0.001 TNFalpha-treated different from TNFalpha+WT BC and WT P2 oligos, *P < 0.05 TNFalpha-treated different from TNFalpha+MT BC oligo.
###end p 32
###begin p 33
###xml 308 310 296 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 427 429 411 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 445 447 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5D</xref>
###xml 598 600 578 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5D</xref>
###xml 711 714 687 690 <underline xmlns:xlink="http://www.w3.org/1999/xlink">GGG</underline>
###xml 748 756 724 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
###xml 773 775 749 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5D</xref>
###xml 910 912 882 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5D</xref>
###xml 953 956 925 928 <underline xmlns:xlink="http://www.w3.org/1999/xlink">CTC</underline>
###xml 1009 1017 977 985 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
###xml 1034 1036 1002 1004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5D</xref>
###xml 1244 1252 1200 1208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
To determine whether TNFalpha induces NF-kappaB binding to the consensus DNA site of the identified region, we used ELISA to detect bound NF-kappaB p65 subunits. This method was employed as an alternative to the electrophoretic mobility shift assay, as it was reported to be more sensitive and quantitative [54]. DNA binding of p65 was dramatically increased in nuclear extracts of H4 cells after 30 min of TNFalpha treatment (P < 0.001; Figure 5D). This binding was abrogated by incubation of the nuclear extracts with either a competing control wild-type kappaB consensus oligonucleotide (Figure 5D, WT BC oligo) or with a competing oligonucleotide containing a wild-type putative kappaB binding sequence 5'-GGGGACGCCC-3' at position -109 in the P2-COMT promoter (Figure 5D, WT P2 oligo). Conversely, both oligonucleotides containing either a mutated version of the control kappaB consensus sequence (Figure 5D, MT BC oligo) or a mutated sequence 5'-GCTCACGCCC-3' of the putative kappaB binding site of the P2-COMT promoter (Figure 5D, MT P2 oligo) had a minimal effect on TNFalpha-induced p65 binding. Results from these experiments confirm that TNFalpha induces p65 recruitment to the functional kappaB binding site at position -109 in the P2-COMT promoter.
###end p 33
###begin title 34
Discussion
###end title 34
###begin p 35
###xml 63 68 63 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 179 187 175 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
###xml 124 127 <span type="species:ncbi:10116">rat</span>
###xml 293 298 <span type="species:ncbi:9606">human</span>
In the present report, we provide the first demonstration that COMT gene expression is downregulated by TNFalpha in primary rat astrocytes at both protein and mRNA levels. As the P2-COMT promoter controls expression of MB-COMT, the main COMT transcript in brain, this promoter was cloned from human genomic DNA and transfected in H4 astroglioma cells. The activity of the cloned promoter was substantially suppressed by TNFalpha in a time-dependent manner.
###end p 35
###begin p 36
###xml 64 66 64 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P1</italic>
###xml 72 80 72 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 229 231 229 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 234 242 234 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
###xml 319 321 319 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 361 363 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
A number of putative regulatory elements have been described in P1- and P2-COMT promoters, including estrogen response (ER) elements [50] that likely mediate estradiol-dependent downregulation of COMT expression in cell culture [55]. P2-COMT also contains abundant methylation sites associated with cancer development [56], schizophrenia, and bipolar disorder [57]. We identified a novel putative regulatory site - a kappaB consensus sequence that is a potential target for TNFalpha-dependent NF-kappaB activation.
###end p 36
###begin p 37
###xml 279 287 260 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
###xml 375 383 348 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
Next, we demonstrated that TNFalpha-dependent COMT downregulation was indeed mediated by the NF-kappaB pathway. Transient expression of p65, the essential component of NF-kappaB complexes, or IKKbeta, the major positive regulator of NF-kappaB activition, significantly decreased P2-COMT reporter expression. In addition, H4 IkappaBalpha-SR cells lost the ability to regulate P2-COMT promoter expression in response to TNFalpha treatment. The TNFalpha-mediated suppression of endogenous COMT expression was also abrogated in H4 IkappaBalpha-SR cells. Moreover, we confirmed that TNFalpha activated NF-kappaB in H4 astroglioma cells through the canonical IkappaB degradation pathway to trigger p65 nuclear translocation and DNA binding.
###end p 37
###begin p 38
###xml 105 113 101 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
###xml 222 230 214 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
###xml 301 309 289 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
Our data strongly suggest that the putative kappaB binding site 5'-GGGGACGCCC-3' at position -109 of the P2-COMT promoter region is a functional site for NF-kappaB-mediated regulation of COMT expression as deletion of the P2-COMT region containing this site abrogated TNFalpha-dependent inhibition of P2-COMT activity in H4 astroglioma cells. Furthermore, competition experiments performed with the wild type or mutant site-specific oligonucleotides showed that TNFalpha indeed induced recruitment of p65 to this kappaB consensus binding site of the promoter.
###end p 38
###begin p 39
###xml 277 288 265 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 443 445 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 607 610 591 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 624 626 608 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 627 631 611 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink">via </italic>
###xml 693 695 677 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 781 783 765 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 911 916 891 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 991 999 971 979 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
###xml 1178 1186 1158 1166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
###xml 277 287 <span type="species:ncbi:7227">Drosophila</span>
Although NF-kappaB-mediated activation of transcription is well known, the mechanisms of NF-kappaB-mediated repression are poorly established. Probably, the best studied example of transcriptional repression by NF-kappaB complex is described for Dorsal transcription factor, a Drosophila Rel family member that can either activate or repress gene expression through the recruitment of coactivators such as CBP or corepressors such as Groucho [58]. Furthermore, a number of examples have been reported in mammals. NF-kappaB can repress transcription by competing with steroid receptors for a common promoter cis-DNA element [59]via N-myc recruitment to the glutamate transporter gene promoter [53] and through inhibiting histone H4 acetylation at the cytochrome P-450 1A1 promoter [60]. Thus, further experiments should be conducted to address the specific mechanism underlying NF-kappaB-dependent inhibition of COMT gene expression. Interestingly, consequent deletions of 5'fragments of the P2-COMT promoter led to a significant increase in overall basal promoter activity. This result would suggest the presence of a number of putative negatively regulating elements along the P2-COMT promoter other than ER- and kappaB-response elements. Although, to date, no studies have systematically searched for regulators of COMT expression, this finding clearly warrants further research.
###end p 39
###begin p 40
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 243 245 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 246 248 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 366 370 366 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">via </italic>
###xml 503 505 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 737 739 721 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 778 780 762 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 985 987 961 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 988 990 964 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 283 311 <span type="species:ncbi:12721">human immunodeficiency virus</span>
###xml 558 573 <span type="species:ncbi:10090">transgenic mice</span>
###xml 897 900 <span type="species:ncbi:10116">rat</span>
Our results demonstrating that COMT expression is downregulated in astrocytes under inflammatory conditions are in line with those of other studies showing a positive correlation between astrocyte activation and exaggerated pain responses [24,25,61]. Intrathecal injection of gp120 (human immunodeficiency virus-1 envelope glycoprotein) induces mechanical allodynia via the release of proinflammatory cytokines and NF-kappaB activation in spinal cord astrocytes, but not in microglial cells or neurons [62]. Selective inactivation of astroglial NF-kappaB in transgenic mice expressing a dominant negative form of the inhibitor IkappaBalpha leads to a dramatic improvement in functional recovery after contusive spinal cord injury (SCI) [46] and decreases formalin-induced pain [47]. Additionally, several recent studies report cell type-specific NF-kappaB activation by cytokines. For example, in rat brain cultures IL-1 induces NF-kappaB activation in astrocytes, but not in neurons [63,64]. Taken together, these studies unequivocally link NF-kappaB activation in astrocytes to pain states.
###end p 40
###begin p 41
###xml 99 101 95 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 102 104 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 286 288 282 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 289 291 285 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 320 322 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 323 325 319 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 391 393 387 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 394 396 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 406 408 402 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 422 424 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 504 509 500 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 659 660 655 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 780 781 776 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 966 974 958 966 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 651 657 <span type="species:ncbi:9606">humans</span>
###xml 715 718 <span type="species:ncbi:10116">rat</span>
Although activation of the NF-kappaB pathway has been deemed critical for the development of pain [40-42], there are few reports studying NF-kB-dependent pro-nociceptive signaling. Historically, these studies have focused on NF-kB-dependent up-regulation of pro-inflammatory cytokines [25,65], cyclooxygenase-2 (COX-2) [39,43], inducible and neuronal nitric oxide synthases (iNOS and nNOS) [38,41], c-src [48], and c-fos [38]. However, recent studies from our group demonstrated that genetic variants of COMT coding for low enzymatic activity are associated with heightened experimental pain sensitivity and the onset of a myofacial pain condition in humans [5]. Additionally, pharmacologic inhibition of COMT in a rat model of inflammation resulted in elevated pain sensitivity [8]. Together, these data suggest that an NF-kappaB-mediated decrease in COMT expression is likely to contribute to heightened pain sensitivity under inflammatory conditions. A series of in vivo experiments further addressing this hypothesis are currently being conducted in our laboratory.
###end p 41
###begin title 42
Conclusion
###end title 42
###begin p 43
###xml 105 109 105 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">via </italic>
###xml 179 187 171 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
###xml 434 436 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 437 439 421 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
Collectively, our results provide the first evidence that COMT expression is downregulated in astrocytes via recruitment of the NF-kappaB complex to a specific kappaB-site at the P2-COMT promoter. NF-kappaB-mediated inhibition of COMT in the CNS may represent a novel mechanism contributing to inflammatory pain. NF-kappaB is regarded as one of the most important targets for therapeutic intervention against inflammatory conditions [66,67]; thus, elucidating the cellular mechanisms that underlie NF-kappaB-mediated inflammatory pain will promote the development of novel therapies including pharmacologic agents that block COMT-dependent pain signaling.
###end p 43
###begin title 44
Methods
###end title 44
###begin title 45
Cell culture and reagents
###end title 45
###begin p 46
###xml 68 70 68 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 373 375 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 73 78 <span type="species:ncbi:9606">Human</span>
###xml 174 180 <span type="species:ncbi:9913">bovine</span>
Primary astrocytes were isolated and cultured as described earlier [68]. Human H4 astroglioma cells were obtained from ATCC (HTB-148) and cultured in DMEM (Sigma), 10% fetal bovine serum (FBS; HyClone) and 1x penicillin-streptomycin (Invitrogen). H4 cells stably expressing IkappaBalpha-SR were a generous gift from Dr. Baldwin (UNC) and generated as described previously [53]. All oligonucleotides were obtained from MWG-Biotech AG. The pCMV-SPORT-M, pCMV-SPORT-M-p65 and pCMV-SPORT-M-IKKbeta expression vectors were a generous gift provided by Dr. Romanov (Attagene) and 3x-kappaB/luc construct was a gift from Dr. Baldwin (UNC).
###end p 46
###begin title 47
Quantitative real-time RT-PCR
###end title 47
###begin p 48
###xml 370 375 <span type="species:ncbi:9606">human</span>
###xml 445 450 <span type="species:ncbi:9606">human</span>
###xml 521 524 <span type="species:ncbi:10116">rat</span>
###xml 597 600 <span type="species:ncbi:10116">rat</span>
Total RNA was isolated using the Trizol reagent (Invitrogen), treated with RNase free-DNase I (Promega) and reverse transcribed with random primers by Superscript III (Invitrogen). The cDNA was amplified with SYBR Green PCR master mix (Applied Biosystems) using forward and reverse PCR primers (5'-CCAGAGGAGACCCCAGACC-3' and 5'-ACAGCTGCCAACAGCAGAG-3', respectively, for human MB-COMT; 5'-GGAAATCGTGCGTGACATC-3' and 5'-CATGGATGCCAAGGATTC-3', for human beta-actin; 5'-CCAGAGGAGACCCCAGACC and 5'-ACAGCTGCCAACAGCAGAG-3', for rat MB-COMT; and 5'-TGCGGGTCATAAGCTTGC-3' and 5'-CGATCCGAGGGCCTCACTA-3' for rat 18S rRNA) in S2 Real Time PCR machine (Eppendorf). PCR reactions were performed in triplicate. Three independent experiments were performed, and the result of a representative experiment is shown. MB-COMT mRNA levels were normalized to beta-actin RNA or 18S rRNA as an endogenous control.
###end p 48
###begin title 49
Western blot analysis
###end title 49
###begin p 50
10-50 mug of protein lysates from whole cells, nuclear and cytoplasmic extracts, normalized for protein content using a BCA Protein Assay Kit (Pierce), were run on precast Novex Tris-Glycine gels (Invitrogen), blotted onto nitrocellose (Whatman), and blocked in TBST with 5% nonfat dry milk. The following antibodies were used: COMT (Chemicon, AB5873), beta-actin (I-19) (Santa Cruz, SC-1616), IkappaBalpha (C-21) (Santa Cruz, SC-371), p65 (Cell Signaling, #3034), and p50 (Santa Cruz, SC-7178). Chemiluminescence was detected in ImageQuant-ECL Imaging System (GE Healthcare) and images were analyzed using ImageQuant TL software (GE Healthcare). Blots from three independent experiments were densitometrically analysed and the values normalized to the beta-actin control, with untreated group set to 100%.
###end p 50
###begin title 51
###xml 11 16 <span type="species:ncbi:9606">human</span>
Cloning of human P2-COMT distal promoter
###end title 51
###begin p 52
###xml 8 11 8 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">U1 </bold>
###xml 14 23 14 23 <underline xmlns:xlink="http://www.w3.org/1999/xlink">CCTACGCGT</underline>
###xml 51 54 51 54 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D1 </bold>
###xml 57 66 57 66 <underline xmlns:xlink="http://www.w3.org/1999/xlink">CGAAGATCT</underline>
###xml 173 181 173 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
###xml 469 477 469 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 195 200 <span type="species:ncbi:9606">human</span>
###xml 469 476 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
Primers U1 5'-CCTACGCGTGCTCCTCTGGCGGAAAGGAA-3' and D1 5'-CGAAGATCTACCTCTCCCGCGACGGCCCG-3', with added Mlu I and Bgl II restriction sites, respectively, were used to amplify P2-COMT from 50 ng of human genomic DNA with GeneAmp PCR kit (Applied Biosystems). The 1.5 kb PCR product was digested by Mlu I and Bgl II restrictases (NEB), gel-purified, ligated into pGL3 Luciferase Reporter Vector (Promega) using Rapid DNA Ligation Kit (Roche) and transformed into competent E. coli DH5alpha cells (Invitrogen). Recombinant plasmids were isolated using EndoFree Plasmid Kit (Qiagen) and sequenced at UNC sequencing facility. Putative regulatory elements were determined with TFSearch database .
###end p 52
###begin title 53
###xml 43 48 <span type="species:ncbi:9606">human</span>
Construction of serial 5'-end deletions of human P2-COMT/Luc clone
###end title 53
###begin p 54
###xml 85 97 85 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT/Luc </italic>
###xml 206 209 206 209 <bold xmlns:xlink="http://www.w3.org/1999/xlink">U2 </bold>
###xml 212 221 212 221 <underline xmlns:xlink="http://www.w3.org/1999/xlink">CCTACGCGT</underline>
###xml 250 252 250 252 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D1</bold>
###xml 272 278 272 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Del. 1</italic>
###xml 284 287 284 287 <bold xmlns:xlink="http://www.w3.org/1999/xlink">U3 </bold>
###xml 290 299 290 299 <underline xmlns:xlink="http://www.w3.org/1999/xlink">CCTACGCGT</underline>
###xml 327 330 327 330 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D1 </bold>
###xml 334 340 334 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Del. 2</italic>
###xml 565 567 565 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
Serial deletions were generated by PCR amplification of corresponding fragments from P2-COMT/Luc clone using forward primers, containing Mlu I restriction site, and reverse primers, containing Bgl II site, U2 5'-CCTACGCGTGCGGACACCCTCACGAGGACA-3' and D1, respectively, for Del. 1, and U3 5'-CCTACGCGTCCACCGGAAGCGCCCTCCTA-3' and D1 for Del. 2. The amplified fragments were digested by Mlu I and Bgl II, purified from the agarose gel and cloned into pGL3 reporter vector. Deletions were confirmed by sequencing. The nucleotide numeration was based on Tenhunen et al. [11].
###end p 54
###begin title 55
Transient transfection, luciferase and beta-galactosidase assays
###end title 55
###begin p 56
###xml 45 46 45 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
Cells were seeded into 12-well plates (5 x 104cells/well) and transfected with 500 ng of total DNA using FuGene 6 reagent (Roche). Normally, up to 400 ng of P2-COMT luciferase reporter and 30 ng of control plasmid for transfection efficiency (pSV-beta-galactosidase vector, Promega) were used for transfection. The amount of DNA was kept constant by addition of pCMV-Sport-M vector with no insert. Cells were treated by TNFalpha (R&D Systems) and harvested 48 h after transfection. Luciferase activity was determined using Luciferase Assay System (Promega) and normalized for transfection efficiency by measuring the beta-galactosidase activity using a beta-Galactosidase Enzyme Assay System (Promega). Transfections were performed in triplicate, and a representative experiment is shown.
###end p 56
###begin title 57
ELISA for activated NF-kappaB
###end title 57
###begin p 58
###xml 306 309 294 297 <underline xmlns:xlink="http://www.w3.org/1999/xlink">GGG</underline>
###xml 316 319 304 307 <underline xmlns:xlink="http://www.w3.org/1999/xlink">GGG</underline>
###xml 305 325 293 313 <bold xmlns:xlink="http://www.w3.org/1999/xlink">G<underline>GGG</underline>ACGCCCG<underline>GGG</underline>ACGCCC</bold>
###xml 352 353 340 341 <bold xmlns:xlink="http://www.w3.org/1999/xlink">G</bold>
###xml 353 356 341 344 <underline xmlns:xlink="http://www.w3.org/1999/xlink">CTC</underline>
###xml 363 366 351 354 <underline xmlns:xlink="http://www.w3.org/1999/xlink">CTC</underline>
###xml 356 372 344 360 <bold xmlns:xlink="http://www.w3.org/1999/xlink">ACGCCCG<underline>CTC</underline>ACGCCC</bold>
###xml 408 416 396 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2-COMT </italic>
NF-kappaB activation was measured using TransAM NF-kappaB p65 Chemi Kit (Active Motif). Cell lysates were tested for their ability to bind to a plate-immobilized oligonucleotide containing a kappaB consensus binding site (5'-GGGACTTTCC-3'). Competition experiments were performed with the wild-type (ACCGCGGGGACGCCCGGGGACGCCCCGACC) and mutant (5'-ACCGCGCTCACGCCCGCTCACGCCCCGACC) oligonucleotides specific to P2-COMT kappaB binding site and kappaB wild-type and mutated consensus oligonucleotides provided by the manufacturer. The wild-type but not mutated oligonucleotides were expected to compete with NF-kappaB for binding. Chemiluminescence was measured in 1420 Multilabel Counter Victor3 (PerkinElmer). Nuclear extracts were prepared using Nuclear Extract Kit (Active Motif).
###end p 58
###begin title 59
Statistical Analysis
###end title 59
###begin p 60
###xml 127 129 127 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Protein, mRNA, and promoter activity data were analyzed by paired t-test and analysis of variance (ANOVA) with post-hoc tests. P < 0.05 was considered to be statistically significant.
###end p 60
###begin title 61
List of abbreviations
###end title 61
###begin p 62
COMT: catechol-O-methyltransferase; IkappaBalpha: inhibitory factor kappaB; IKK: IkappaB kinase; NF-kappaB: nuclear factor kappaB; TNFalpha: tumor necrosis factor alpha.
###end p 62
###begin title 63
Competing interests
###end title 63
###begin p 64
The authors declare that they have no competing interests.
###end p 64
###begin title 65
Authors' contributions
###end title 65
###begin p 66
IET and LBD conceived of the study, and IET, AGN, SW, MC, and LQ performed experiments. IET, AGN, and LBD participated in writing of the manuscript. All authors read and approved the final manuscript.
###end p 66
###begin title 67
Acknowledgements
###end title 67
###begin p 68
###xml 235 242 227 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#954;B </italic>
We thank Drs. Maixner and Baldwin for helpful and inspiring discussions, Kathryn Satterfield, Brad Cooke, and Dustin Gibson for technical assistance, Dr. Sitcheran for helpful discussions and a gift of H4 IkappaBalpha-SR cell line and kappaB reporter, and Dr. Romanov for p65 and IKKbeta expression vectors. This work was supported by the NIH/NIDCR RO1 DE016558 grant to LBD and the NIH/NICHHD K12 HD052191 grant to AGN.
###end p 68
###begin article-title 69
O-methylation of catechol amines in vivo
###end article-title 69
###begin article-title 70
Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors
###end article-title 70
###begin article-title 71
Catechol-O-Methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis
###end article-title 71
###begin article-title 72
Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond
###end article-title 72
###begin article-title 73
Genetic basis for individual variations in pain perception and the development of a chronic pain condition
###end article-title 73
###begin article-title 74
Catechol-O-methyltransferase gene polymorphisms are associated with multiple pain-evoking stimuli
###end article-title 74
###begin article-title 75
###xml 65 73 <span type="species:ncbi:9606">patients</span>
Erythrocyte catechol-O-methyltransferase activity in facial pain patients
###end article-title 75
###begin article-title 76
Catechol-O-methyltransferase inhibition increases pain sensitivity through activation of both beta2- and beta3-adrenergic receptors
###end article-title 76
###begin article-title 77
###xml 42 45 <span type="species:ncbi:10116">rat</span>
Molecular cloning and characterization of rat liver catechol-O-methyltransferase
###end article-title 77
###begin article-title 78
###xml 32 37 <span type="species:ncbi:9606">human</span>
Cloning and characterization of human placental catechol-O-methyltransferase cDNA
###end article-title 78
###begin article-title 79
###xml 28 33 <span type="species:ncbi:9606">human</span>
Genomic organization of the human catechol O-methyltransferase gene and its expression from two distinct promoters
###end article-title 79
###begin article-title 80
###xml 59 64 <span type="species:ncbi:9606">human</span>
Distribution of catechol-O-methyltransferase expression in human central nervous system
###end article-title 80
###begin article-title 81
###xml 17 20 <span type="species:ncbi:10116">rat</span>
Structure of the rat catechol-O-methyltransferase gene: separate promoters are used to produce mRNAs for soluble and membrane-bound forms of the enzyme
###end article-title 81
###begin article-title 82
###xml 12 17 <span type="species:ncbi:9606">human</span>
Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme
###end article-title 82
###begin article-title 83
###xml 76 81 <span type="species:ncbi:9606">human</span>
Expression of multiple catechol-o-methyltransferase (COMT) mRNA variants in human brain
###end article-title 83
###begin article-title 84
###xml 48 53 <span type="species:ncbi:9606">human</span>
###xml 58 61 <span type="species:ncbi:10116">rat</span>
Catechol O-methyltransferase mRNA expression in human and rat brain: evidence for a role in cortical neuronal function
###end article-title 84
###begin article-title 85
###xml 39 42 <span type="species:ncbi:10116">rat</span>
###xml 109 112 <span type="species:ncbi:10116">rat</span>
Catechol-O-methyltransferase (COMT) in rat brain: immunoelectron microscopic study with an antiserum against rat recombinant COMT protein
###end article-title 85
###begin article-title 86
Cloning, expression and structure of catechol-O-methyltransferase
###end article-title 86
###begin article-title 87
Immunohistochemical demonstration of catechol-o-methyltransferase in mammalian brain
###end article-title 87
###begin article-title 88
Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia
###end article-title 88
###begin article-title 89
Central proinflammatory cytokines and pain enhancement
###end article-title 89
###begin article-title 90
The tetrapartite synapse: path to CNS sensitization and chronic pain
###end article-title 90
###begin article-title 91
Immune and glial cell factors as pain mediators and modulators
###end article-title 91
###begin article-title 92
Glial-cytokine-neuronal interactions underlying the mechanisms of persistent pain
###end article-title 92
###begin article-title 93
Complete Freunds adjuvant-induced peripheral inflammation evokes glial activation and proinflammatory cytokine expression in the CNS
###end article-title 93
###begin article-title 94
###xml 43 46 <span type="species:ncbi:10116">rat</span>
Peri-sciatic administration of recombinant rat TNF-alpha induces mechanical allodynia via upregulation of TNF-alpha in dorsal root ganglia and in spinal dorsal horn: the role of NF-kappa B pathway
###end article-title 94
###begin article-title 95
Tumor necrosis factor-alpha as a biochemical marker of pain and outcome in temporomandibular joints with internal derangements
###end article-title 95
###begin article-title 96
Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity
###end article-title 96
###begin article-title 97
Cytokines in sural nerve biopsies from inflammatory and non-inflammatory neuropathies
###end article-title 97
###begin article-title 98
Signalling pathways of the TNF superfamily: a double-edged sword
###end article-title 98
###begin article-title 99
TNF-R1 signaling: a beautiful pathway
###end article-title 99
###begin article-title 100
NF-kappaB as a therapeutic target in chronic inflammation: recent advances
###end article-title 100
###begin article-title 101
NF-kappa B: a crucial transcription factor for glial and neuronal cell function
###end article-title 101
###begin article-title 102
NF-kappaB in neuronal plasticity and neurodegenerative disorders
###end article-title 102
###begin article-title 103
Signaling via NF-kappaB in the nervous system
###end article-title 103
###begin article-title 104
IkappaB kinases: key regulators of the NF-kappaB pathway
###end article-title 104
###begin article-title 105
Missing pieces in the NF-kappaB puzzle
###end article-title 105
###begin article-title 106
Activation of transcription factors of nuclear factor kappa B, activator protein-1 and octamer factors in hyperalgesia
###end article-title 106
###begin article-title 107
Spinal NF-kB activation induces COX-2 upregulation and contributes to inflammatory pain hypersensitivity
###end article-title 107
###begin article-title 108
###xml 50 53 <span type="species:ncbi:10116">rat</span>
Increased activation of nuclear factor kappa B in rat lumbar dorsal root ganglion neurons following partial sciatic nerve injuries
###end article-title 108
###begin article-title 109
Inducible nitric oxide synthase expression in brain cortex after acute restraint stress is regulated by nuclear factor kappaB-mediated mechanisms
###end article-title 109
###begin article-title 110
Reciprocal regulation of nuclear factor kappa B and its inhibitor ZAS3 after peripheral nerve injury
###end article-title 110
###begin article-title 111
###xml 106 110 <span type="species:ncbi:10116">rats</span>
Specific Inhibition of IkappaB kinase reduces hyperalgesia in inflammatory and neuropathic pain models in rats
###end article-title 111
###begin article-title 112
Cytokine involvement in dynorphin-induced allodynia
###end article-title 112
###begin article-title 113
###xml 139 142 <span type="species:ncbi:10116">rat</span>
Lentiviral-mediated targeted NF-kappaB blockade in dorsal spinal cord glia attenuates sciatic nerve injury-induced neuropathic pain in the rat
###end article-title 113
###begin article-title 114
Inhibition of astroglial nuclear factor kappaB reduces inflammation and improves functional recovery after spinal cord injury
###end article-title 114
###begin article-title 115
###xml 78 82 <span type="species:ncbi:10090">mice</span>
Transgenic glial nuclear factor-kappa B inhibition decreases formalin pain in mice
###end article-title 115
###begin article-title 116
Modulation of peripheral inflammation in sensory ganglia by nuclear factor (kappa)B decoy oligodeoxynucleotide: involvement of SRC kinase pathway
###end article-title 116
###begin article-title 117
Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-alpha
###end article-title 117
###begin article-title 118
###xml 67 72 <span type="species:ncbi:9606">human</span>
Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription
###end article-title 118
###begin article-title 119
Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL
###end article-title 119
###begin article-title 120
Tumor necrosis factor: an apoptosis JuNKie?
###end article-title 120
###begin article-title 121
Positive and negative regulation of EAAT2 by NF-kappaB: a role for N-myc in TNFalpha-controlled repression
###end article-title 121
###begin article-title 122
Multiple transcription factor profiling by enzyme-linked immunoassay
###end article-title 122
###begin article-title 123
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human catechol-O-methyltransferase down-regulation by estradiol
###end article-title 123
###begin article-title 124
Multiple promoters of catechol-O-methyltransferase gene are selectively inactivated by CpG hypermethylation in endometrial cancer
###end article-title 124
###begin article-title 125
Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder
###end article-title 125
###begin article-title 126
###xml 35 45 <span type="species:ncbi:7227">Drosophila</span>
A conserved signaling pathway: the Drosophila toll-dorsal pathway
###end article-title 126
###begin article-title 127
Identification of a negative regulatory cis-element in the enhancer core region of the prostate-specific antigen promoter: implications for intersection of androgen receptor and nuclear factor-kappaB signalling in prostate cancer cells
###end article-title 127
###begin article-title 128
Mechanism of suppression of cytochrome P-450 1A1 expression by tumor necrosis factor-alpha and lipopolysaccharide
###end article-title 128
###begin article-title 129
###xml 63 67 <span type="species:ncbi:10116">rats</span>
GFAP expression in lumbar spinal cord of naive and neuropathic rats treated with MK-801
###end article-title 129
###begin article-title 130
###xml 63 66 <span type="species:ncbi:10116">rat</span>
Involvement of spinal cord nuclear factor kappaB activation in rat models of proinflammatory cytokine-mediated pain facilitation
###end article-title 130
###begin article-title 131
###xml 77 80 <span type="species:ncbi:10116">rat</span>
Activation of astrocyte intracellular signaling pathways by interleukin-1 in rat primary striatal cultures
###end article-title 131
###begin article-title 132
Cell type-specific interleukin-1beta signaling in the CNS
###end article-title 132
###begin article-title 133
###xml 83 87 <span type="species:ncbi:10116">rats</span>
Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats
###end article-title 133
###begin article-title 134
NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis
###end article-title 134
###begin article-title 135
Pathophysiology and treatment of pain in joint disease
###end article-title 135
###begin article-title 136
###xml 69 74 <span type="species:ncbi:10090">mouse</span>
Reduction by naloxone of lipopolysaccharide-induced neurotoxicity in mouse cortical neuron-glia co-cultures
###end article-title 136

